Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at...

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...

ARCH BIOPARTNERS SAFELY COMPLETES  EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final...